Aquipta
atogepant
Table of contents
Overview
Aquipta is a medicine used to prevent migraines in adults who have migraines at least 4 days a month.
Aquipta contains the active substance atogepant.
-
List item
Aquipta : EPAR - Medicine Overview (PDF/116.53 KB)
First published: 25/08/2023
EMA/361998/2023 -
-
List item
Aquipta : EPAR - Risk Management Plan (PDF/347.86 KB)
First published: 25/08/2023
Authorisation details
Product details | |
---|---|
Name |
Aquipta
|
Agency product number |
EMEA/H/C/005871
|
Active substance |
atogepant
|
International non-proprietary name (INN) or common name |
atogepant
|
Therapeutic area (MeSH) |
Migraine Disorders
|
Anatomical therapeutic chemical (ATC) code |
N02CD07
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Publication details | |
---|---|
Marketing-authorisation holder |
AbbVie Deutschland GmbH & Co. KG
|
Date of issue of marketing authorisation valid throughout the European Union |
11/08/2023
|
Contact address |
Knollstrasse |
Product information
Aquipta - EMEA/H/C/005871 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
Aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month